Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.84 |
| ▸ | KIT | P10721 | 8/20 | 0.84 |
| ▸ | BCR | P11274 | 8/20 | 0.84 |
| ▸ | LCK | P06239 | 4/20 | 0.84 |
| ▸ | LYN | P07948 | 4/20 | 0.84 |
| ▸ | FLT3 | P36888 | 4/20 | 0.84 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.84 |
| ▸ | LDLR | P01130 | 2/20 | 0.84 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
| ▸ | CA12 | O43570 | 1/20 | 0.84 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.84 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.84 |
| ▸ | STK10 | O94804 | 1/20 | 0.84 |
| ▸ | CA1 | P00915 | 1/20 | 0.84 |
| ▸ | CA2 | P00918 | 1/20 | 0.84 |
| ▸ | RAF1 | P04049 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL7901 | 0.91 | ABL1 (1.00) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL29366964 | 0.91 | ABL1 (1.00) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL29580067 | 0.91 | ABL1 (1.00) | ABL1PDGFRAPDGFRBKITBCR | |
| SCHEMBL3533748 | 0.91 | ABL1 (0.70) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL9990634 | 0.91 | ABL1 (0.99) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL1459790 | 0.91 | ABL1 (0.99) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL1984397 | 0.91 | ABL1 (0.99) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL434496 | 0.91 | ABL1 (0.99) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL31005052 | 0.91 | ABL1 (0.99) | ABL1PDGFRAPDGFRBKITBCR | |
| Nilotinib SCHEMBL28569394 | 0.91 | ABL1 (0.99) | ABL1PDGFRAPDGFRBKITBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2023-11-07 | — | — | US | disclosed |
| US-20210361641-A1 | Inhibitors of DUX4 Induction for Regulation of Muscle Function | GENEA BIOCELLS US, INC. | 2021-11-25 | — | — | US | disclosed |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-07-20 | — | — | US | disclosed |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | SONIC MASTER LIMITED (VG) | 2020-10-22 | — | — | US | disclosed |
| US-20140179711-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | US | disclosed |
| US-8680103-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1711481-B1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | ABL1 77/4885PDGFRA 439/4885PDGFRB 309/4885 |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | ABL1 77/4885PDGFRA 439/4885PDGFRB 309/4885 |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | ABL1 77/4885PDGFRA 439/4885PDGFRB 309/4885 |
| US-20140179711-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | ABL1 26/4885PDGFRA 194/4885PDGFRB 205/4885 |
| US-20210361641-A1 | Inhibitors of DUX4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | ABL1 77/4885PDGFRA 439/4885PDGFRB 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.